In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Bayer licenses Natrecor from Scios for $60mm

28 Oct 1999

Executive Summary

Bayer has licensed worldwide rights to Scios's congestive heart failure (CHF) drug Natrecor (nesiritide). Bayer will pay (uf)$20mm cash upfront, up to an additional $40mm upon US, European, and Japanese regulatory milestones, plus sales royalties.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By